Studied genes | Hospitalization (n;%) | Total n = 83 | |
---|---|---|---|
Yes, n = 61 (73.4%) | No, n = 22 (26.5%) | ||
4 (6.5%) | 2 (9.0%) | 6 (7.2%) | |
8 (13.1%) | 5 (22.7%) | 13 (15.6%) | |
4 (6,5%) | 0 | 4 (4.8%) | |
45 (73.7%) | 15 (68.1%) | 60 (72.2%) | |
10 (16.3%) | 0 | 10 (12.0%) | |
2 (3.2%) | 1 (4.5%) | 3 (3.6%) | |
2 (3.2%) | N0 | 2 (2.4%) |
Characteristics of the study group | Hospitalization (n; %) | OR (95% CI) | p-value | ||
---|---|---|---|---|---|
Yes, n = 61 (73.4%) | No, n = 22 (26.5%) | Total, N = 83 | |||
Age (years) by categories [n; %] | |||||
< = 18 years | 15 (24.5%) | 1 (4.5%) | 16 (19.2%) | 2.5 (0.20–32.99) | 0.027 |
19–64 years | 12 (19.6%) | 2 (9.0%) | 14 (16.8%) | 1.00 (ref.) | |
> = 65 years | 34 (55.7%) | 19 (86.3%) | 53 (63.8%) | 8.4 (1.03–68.49) | |
Gender [n; %] | |||||
Female | 26 (42.6%) | 12 (54.5%) | 38 (45.7%) | 0.6 (0.23–1.65) | 0.454 |
Male | 35 (57.3%) | 10 (45.4%) | 45 (54.2%) | ||
The positive CRA (Congo Red Agar) biofilm test result (n; %) | |||||
yes | 45 (73.7%) | 10 (45.4%) | 55 (66.2%) | 3.3 (1.22–9.31) | 0.016 |
no | 16 (26.2%) | 12 (54.5%) | 28 (33.7%) |
Antimicrobial category | Antimicrobial agent | Hospitalization n (%) | Total, N = 83 | |
---|---|---|---|---|
Yes, n = 61 (73.4%) | No, n = 22 (26.5%) | |||
Aminoglycosides | Gentamicin | 4 (6.5%) | 1 (4.5%) | 5 (6.0%) |
Amikacin | 5 (8.1%) | 3 (13.6%) | 8 (9.6%) | |
Tobramycin | 9 (14.7%) | 5 (22.7%) | 14 (16.8%) | |
Neomycin | 37 (60.6%) | 11 (50.0%) | 48 (57.8%) | |
Fluoroquinolones | Ciprofloxacin | 4 (6.5%) | 7 (31.8%) | 11 (13.2%) |
Moxifloxacin | 2 (3.2%) | 4 (18.1%) | 6 (7.2%) | |
Folate pathway inhibitors | Trimethoprim/sulfamethoxazole | 3 (4.9%) | 2 (9.0%) | 5 (6.0%) |
Lincosamides | Clindamycin | 13 (21.3%) | 8 (36.3%) | 21 (25.3%) |
Macrolides | Erythromycin | 13 (21.3%) | 8 (36.3%) | 21 (25.3%) |
Phenicols | Chloramphenicol | 4 (6.5%) | 1 (4.5%) | 5 (6.0%) |
Tetracyclines | Tetracycline | 11 (18.0%) | 3 (13.6%) | 14 (16.8%) |
Non-susceptible to antimicrobial agents in (above) categories | ||||
fully susceptible (0 categories) | 37 (60.6%) | 6 (27.2%) | 61 (73.4%) | |
one category | 25 (40.9%) | 4 (18.1%) | 29 (34.9%) | |
2 categories | 12 (19.6%) | 6 (27.2%) | 18 (21.6%) | |
3 categories | 5 (8.1%) | 1 (4.5%) | 6 (7.2%) | |
4 categories | 2 (3.2%) | 1 (4.5%) | 3 (3.6%) | |
5 categories or more | 2 (3.2%) | 4 (18.1%) | 5 (6.0%) | |
MRSA, yes | 3 (4.9%) | 2 (9.0%) | 5 (6.0%) | |
MLSB, yes | 14 (22.9%) | 8 (36.3%) | 22 (26.5%) |